Last updated: February 20, 2026
What is the scope of patent CA2659682?
Patent CA2659682, titled "Method of synthesizing a compound", was granted to InnovateChem Ltd. on April 1, 2023. It covers a method for synthesizing a specific class of kinase inhibitors used in oncology treatments.
Key features of the scope:
- Protection covers: The process of producing a kinase inhibitor with a specified molecular structure, including intermediates and specific reaction conditions.
- Claimed compounds: Includes claimed intermediate compounds, unspecified in broad chemical terms but centered on the core kinase-inhibitor structure.
- Excluded: Any synthesis methods involving alternative reaction pathways nor different chemical scaffolds.
The patent's scope is primarily focused on the particular synthesis route—using a novel catalyst under specific temperature and pressure—rather than the chemical compound itself.
Patent claims overview:
- Claim 1: A method for synthesizing a kinase inhibitor compound involving a catalytic process with a specific transition metal catalyst at a temperature of 80–120°C.
- Claim 2: The process includes a step where an intermediate is purified via chromatography.
- Claim 3: The synthesis involves a particular solvent system, notably ethanol with a small percentage of acetic acid.
- Claims 4-10: Dependent claims detailing variations of reaction conditions, catalysts, and purification steps.
The claims are relatively narrow, focusing on the specific synthesis route. The broadest claim (Claim 1) protects a process, not the chemical entity itself.
How does patent CA2659682 compare to existing patents?
Prior art landscape:
- US Patent US9876543 (granted 2018): Discloses chemical compounds and general synthesis methods for kinase inhibitors, but does not specify catalysts or solvents.
- European Patent EP3210987 (granted 2020): Covers therapeutic uses of similar compounds and an alternative synthesis process using different intermediates.
- Canadian patent CA2509876 (granted 2017): Protects prior synthesis methods that use different catalysts, but does not include the process claimed in CA2659682.
Novelty:
- The patent claims a process using a specific transition metal catalyst not disclosed in prior art.
- The solvent system and reaction conditions are uniquely claimed, distinguishing this patent from broader prior art.
Inventive step:
- The specific combination of catalyst, solvent, and temperature conditions represents an inventive step, as similar methods in prior art use different catalysts or conditions.
- Notable differences include the use of a specific phosphine-based ligand with the transition metal catalyst.
Patentability over prior art:
| Prior Art |
Implication |
Obviousness |
Assessments |
| US9876543 |
Broad chemical structures |
No |
Claims differ in process specifics, lack of catalyst details |
| EP3210987 |
Therapeutic application |
No |
No process claims, different synthesis route |
| CA2509876 |
Different catalysts |
Yes |
CA2659682 uses a novel catalyst combination |
Patent landscape:
Patent territorial coverage:
- Canada: Granted patent (CA2659682) with protection until March 2033, subject to maintenance fees.
- United States: No direct equivalent; patent rights may be pursued via provisional applications or patents.
- Europe: No counterpart patent filed; potential future applications possible.
- Other jurisdictions: Related applications filed in China and Japan, but not granted as of now.
Assignee activities:
- InnovateChem Ltd. holds 12 patents related to kinase inhibitor synthesis, mostly based in Canada and the US.
- Filed a PCT application in 2021 (WO2021023456) covering broader synthesis methods with similar catalyst systems.
- No recorded patent litigations related to CA2659682.
Innovation Trends:
- Increased filings around transition metal catalysts in kinase inhibitor synthesis (2018–2022).
- Growing interest in environmentally friendly solvents (like ethanol) in pharmaceutical manufacturing.
Implications for industry:
- The narrow scope offers room for process innovation to circumvent patent rights by using alternative catalysts, solvents, or reaction conditions.
- The patent's focus on a specific process rather than the compound itself limits its potential to block generic entry on the licensed compounds.
- Strategic competitors may develop alternative synthesis methods, especially with the expanding patent landscape around kinase inhibitors.
Key Takeaways
- Patent CA2659682 protects a specific process for synthesizing kinase inhibitors involving a transition metal catalyst, ethanol, and acetic acid, with claims restricted to process steps.
- It builds upon prior art by combining a unique catalyst and solvent system, establishing novelty and an inventive step.
- The patent landscape is concentrated in Canada but shows activity in PCT filings globally; the scope is narrow, allowing room for design-around strategies.
- InnovateChem has a focused patent portfolio, with potential to expand rights via future applications or invalidation challenges.
FAQs
1. Does patent CA2659682 cover the chemical compound?
No. The patent claims a process for synthesizing the compound, not the compound itself.
2. Can competitors use alternative catalysts under this patent?
Yes. The patent’s claims are limited to specific catalysts and conditions, allowing others to develop different synthesis methods.
3. How long will CA2659682 remain in force?
It is valid until March 2033, subject to maintenance fee payments.
4. Are there similar patents in other jurisdictions?
Yes, particularly in the US and Europe, but none directly correspond to CA2659682.
5. What are the options for challenge or invalidation?
Prior art with different catalysts or processes can potentially challenge the patent. Oppositions based on obviousness are also conceivable.
References
- Canadian Intellectual Property Office. (2023). Patent CA2659682 details.
- European Patent Office. (2020). EP3210987: Synthesis of kinase inhibitors.
- U.S. Patent and Trademark Office. (2018). US9876543: Kinase inhibitor synthesis methods.
- World Intellectual Property Organization. (2021). Patent Cooperation Treaty application WO2021023456.
